Lisata Therapeutics Inc. (LSTA) - Total Assets
Based on the latest financial reports, Lisata Therapeutics Inc. (LSTA) holds total assets worth $21.76 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Lisata Therapeutics Inc. (LSTA) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Lisata Therapeutics Inc. - Total Assets Trend (1990–2024)
This chart illustrates how Lisata Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. Explore Lisata Therapeutics Inc. long-term investment intensity to see how much of total assets are deployed in long-term investments.
Lisata Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Lisata Therapeutics Inc.'s total assets of $21.76 Million consist of 98.8% current assets and 1.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 46.3% |
| Accounts Receivable | $900.00K | 2.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $192.00K | 0.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1990–2024)
This chart illustrates how Lisata Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see LSTA market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Lisata Therapeutics Inc.'s current assets represent 98.8% of total assets in 2024, an increase from 90.9% in 1990.
- Cash Position: Cash and equivalents constituted 46.3% of total assets in 2024, up from 0.0% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1990.
- Asset Diversification: The largest asset category is accounts receivable at 2.6% of total assets.
Lisata Therapeutics Inc. Competitors by Total Assets
Key competitors of Lisata Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Lisata Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.72 | 8.03 | 10.08 |
| Quick Ratio | 4.72 | 8.03 | 10.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $17.01 Million | $33.00 Million | $31.82 Million |
Lisata Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Lisata Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.33 |
| Latest Market Cap to Assets Ratio | 0.89 |
| Asset Growth Rate (YoY) | -36.0% |
| Total Assets | $35.00 Million |
| Market Capitalization | $31.05 Million USD |
Valuation Analysis
Near Book Valuation: The market values Lisata Therapeutics Inc.'s assets close to their book value (0.89x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Lisata Therapeutics Inc.'s assets decreased by 36.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Lisata Therapeutics Inc. (1990–2024)
The table below shows the annual total assets of Lisata Therapeutics Inc. from 1990 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $35.00 Million | -36.00% |
| 2023-12-31 | $54.69 Million | -25.11% |
| 2022-12-31 | $73.03 Million | -24.71% |
| 2021-12-31 | $97.01 Million | +169.45% |
| 2020-12-31 | $36.00 Million | +32.59% |
| 2019-12-31 | $27.15 Million | -39.09% |
| 2018-12-31 | $44.58 Million | -29.66% |
| 2017-12-31 | $63.38 Million | +22.27% |
| 2016-12-31 | $51.83 Million | -9.39% |
| 2015-12-31 | $57.21 Million | -54.70% |
| 2014-12-31 | $126.28 Million | +40.59% |
| 2013-12-31 | $89.82 Million | +65.08% |
| 2012-12-31 | $54.41 Million | -64.97% |
| 2011-12-31 | $155.33 Million | +8.60% |
| 2010-12-31 | $143.02 Million | +34.88% |
| 2009-12-31 | $106.03 Million | +5712.30% |
| 2008-12-31 | $1.82 Million | -51.68% |
| 2007-12-31 | $3.78 Million | +215.92% |
| 2006-12-31 | $1.19 Million | +85.94% |
| 2005-12-31 | $642.68K | +546.27% |
| 2004-12-31 | $99.44K | -68.10% |
| 2003-12-31 | $311.69K | -73.66% |
| 2002-12-31 | $1.18 Million | -35.57% |
| 2001-12-31 | $1.84 Million | -60.24% |
| 2000-12-31 | $4.62 Million | -10.69% |
| 1999-12-31 | $5.17 Million | +470.85% |
| 1998-12-31 | $905.79K | +5973.43% |
| 1996-12-31 | $14.91K | -89.05% |
| 1995-12-31 | $136.20K | -98.61% |
| 1994-12-31 | $9.80 Million | +27.27% |
| 1993-12-31 | $7.70 Million | +133.33% |
| 1990-12-31 | $3.30 Million | -- |
About Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more